Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging134
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?106
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions104
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer90
Best of 2022 in prostate cancer and prostatic diseases75
New BPH therapy classification: what really FITs?71
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?63
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction59
Sexual outcomes in men who have sex with men who underwent radical prostatectomy58
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis54
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes45
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study44
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro43
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)43
Concerns regarding prostate cancer screening guidelines in minority populations42
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study41
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis40
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer39
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations39
Feasibility and safety study of the Flostentâ„¢ system (RAPID-I)37
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer37
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study36
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study36
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer35
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts35
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer34
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure33
TRexit is going one step further33
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients32
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy32
Incidence of prostate cancer in transgender women in the US: a large database analysis32
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons31
0.14710521697998